phenylacetic acid has been researched along with Hyperammonemia in 20 studies
phenylacetic acid : A monocarboxylic acid that is toluene in which one of the hydrogens of the methyl group has been replaced by a carboxy group.
Hyperammonemia: Elevated level of AMMONIA in the blood. It is a sign of defective CATABOLISM of AMINO ACIDS or ammonia to UREA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, we used magnetic resonance spectroscopy (MRS) to monitor cerebral glutamine levels, the major reservoir of ammonia, in a gastric bypass patient with hyperammonemic coma undergoing therapy with N-carbamoyl glutamate and the ammonia-scavenging agents, sodium phenylacetate and sodium benzoate." | 7.85 | Brain MRS glutamine as a biomarker to guide therapy of hyperammonemic coma. ( Bellinger, A; Berry, GT; Cohen, DE; Frank, NY; Gershanik, EF; Goldberg, AD; Levy, BD; Lin, AP; Lynch, R; McFaline-Figueroa, JR; Merugumala, SK; O'Donnell-Luria, AH; Rohr, F; Samuels, MA; Simon, T; Tchekmedyian, V; Waisbren, SE, 2017) |
| "We report the results of a 25-year, open-label, uncontrolled study of sodium phenylacetate and sodium benzoate therapy (Ammonul, Ucyclyd Pharma) in 299 patients with urea-cycle disorders in whom there were 1181 episodes of acute hyperammonemia." | 5.12 | Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. ( Berry, GT; Berry, SA; Brusilow, SW; Enns, GM; Hamosh, A; Rhead, WJ, 2007) |
| "The purpose of the study was to evaluate the influence of establishing a protocol for the use of combined sodium benzoate and sodium phenylacetate (SBSP) (Ammonul®) to treat acute hyperammonemia." | 3.91 | Influence of implementing a protocol for an intravenously administered ammonia scavenger on the management of acute hyperammonemia in a pediatric intensive care unit. ( Brossier, D; Goyer, I; Jouvet, P; Marquis, C; Mitchell, G; Ozanne, B; Ziani, L, 2019) |
| "Patients with neonatal urea cycle defects (UCDs) typically experience severe hyperammonemia during the first days of life, which results in serious neurological injury or death." | 3.88 | Prenatal treatment of ornithine transcarbamylase deficiency. ( Akula, VP; Alcorn, D; Benitz, WE; Bernstein, JA; Berquist, WE; Blumenfeld, YJ; Castillo, RO; Concepcion, W; Cowan, TM; Cox, KL; Cusmano, K; Enns, GM; Esquivel, CO; Hintz, SR; Homeyer, M; Hudgins, L; Hurwitz, M; Lyell, DJ; Palma, JP; Schelley, S; Summar, ML; Wilnai, Y, 2018) |
| " Therefore, we used magnetic resonance spectroscopy (MRS) to monitor cerebral glutamine levels, the major reservoir of ammonia, in a gastric bypass patient with hyperammonemic coma undergoing therapy with N-carbamoyl glutamate and the ammonia-scavenging agents, sodium phenylacetate and sodium benzoate." | 3.85 | Brain MRS glutamine as a biomarker to guide therapy of hyperammonemic coma. ( Bellinger, A; Berry, GT; Cohen, DE; Frank, NY; Gershanik, EF; Goldberg, AD; Levy, BD; Lin, AP; Lynch, R; McFaline-Figueroa, JR; Merugumala, SK; O'Donnell-Luria, AH; Rohr, F; Samuels, MA; Simon, T; Tchekmedyian, V; Waisbren, SE, 2017) |
| "Urea cycle enzyme deficiency (UCED) patients with hyperammonemia are treated with sodium benzoate (SB) and sodium phenylacetate (SPA) to induce alternative pathways of nitrogen excretion." | 3.85 | Saline is as effective as nitrogen scavengers for treatment of hyperammonemia. ( de Sain-van der Velden, MGM; Favier, RP; Fieten, H; Holwerda-Loof, NE; Mesu, SJ; Rothuizen, J; Spee, B; van der Ham, M; van Geijlswijk, IM; van Straten, G; Verhoeven-Duif, NM, 2017) |
| "An infant with a suspected inborn metabolism error was treated with a metabolic cocktail of intravenous sodium phenylacetate (NaPh) and sodium benzoate (NaBz) for hyperammonemia." | 3.74 | Phenylacetate and benzoate clearance in a hyperammonemic infant on sequential hemodialysis and hemofiltration. ( Barletta, GM; Bunchman, TE; Crumb, TL; Gardner, JJ; McBryde, KD; Winters, JW, 2007) |
| "Ammunol (sodium phenylacetate/sodium benzoate) is an intravenously administered, investigational drug used for the treatment of acute hyperammonemia in infants, children, and adults with urea cycle enzyme deficiencies." | 3.72 | Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers. ( Altincatal, A; MacArthur, RB; Tuchman, M, 2004) |
| " This involves the long-term use of oral sodium phenylbutyrate, arginine supplements, or both, depending on the specific enzyme deficiency, and treatment of acute hyperammonemic crises with intravenous sodium benzoate/sodium phenylacetate plus arginine." | 2.41 | Alternative pathway therapy for urea cycle disorders: twenty years later. ( Batshaw, ML; MacArthur, RB; Tuchman, M, 2001) |
| " Glycerol phenylbutyrate (GPB) is safe and effective in reducing ammonia levels in patients with UCD above 2 months of age." | 1.62 | Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders. ( Ah Mew, N; Bannick, AA; Berry, SA; Canavan, C; Conway, RL; Diaz, GA; Hainline, B; Inbar-Feigenberg, M; Kok, T; Lichter-Konecki, U; Longo, N; McCandless, SE; Porter, MH; Schulze, A; Vescio, T; Zori, R, 2021) |
| "Hyperammonemia is a rare, often fatal complication after transplantation." | 1.43 | Hyperammonemia Syndrome After Lung Transplantation: A Single Center Experience. ( Bain, KB; Byers, DE; Chen, C; Hachem, RR; Iuppa, JA; Patterson, GA; Trulock, EP; Witt, CA; Yusen, RD, 2016) |
| "Available medications for treating urea cycle disorders include sodium benzoate (BA), sodium phenylacetate (PAA), and sodium phenylbutyrate (PBA) and are given to provide alternate routes for disposition of waste nitrogen excretion." | 1.36 | Simultaneous LC-MS/MS determination of phenylbutyrate, phenylacetate benzoate and their corresponding metabolites phenylacetylglutamine and hippurate in blood and urine. ( Herebian, D; Laryea, MD; Mayatepek, E; Meissner, T, 2010) |
| " The prepared sodium phenylacetate powder was orally administered to a 16-year-old patient with CTLN2 at a dosage of 12 g/d." | 1.31 | Successful treatment of severe hyperammonemia using sodium phenylacetate powder prepared in hospital pharmacy. ( Hashimoto, G; Honda, S; Horiuchi, R; Kaneko, H; Konno, Y; Nagai, K; Oshima, Y; Sekizuka, M; Tomomasa, T; Yamamoto, K, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (40.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Endo, F | 2 |
| Nakamura, K | 2 |
| Sano, Y | 2 |
| Dote, N | 2 |
| Shimizu, K | 2 |
| Koumura, E | 2 |
| Raina, R | 1 |
| Bedoyan, JK | 1 |
| Lichter-Konecki, U | 2 |
| Jouvet, P | 2 |
| Picca, S | 1 |
| Mew, NA | 1 |
| Machado, MC | 1 |
| Chakraborty, R | 1 |
| Vemuganti, M | 1 |
| Grewal, MK | 1 |
| Bunchman, T | 1 |
| Sethi, SK | 1 |
| Krishnappa, V | 1 |
| McCulloch, M | 1 |
| Alhasan, K | 1 |
| Bagga, A | 1 |
| Basu, RK | 1 |
| Schaefer, F | 1 |
| Filler, G | 1 |
| Warady, BA | 1 |
| Longo, N | 1 |
| Diaz, GA | 1 |
| Schulze, A | 1 |
| Inbar-Feigenberg, M | 1 |
| Conway, RL | 1 |
| Bannick, AA | 1 |
| McCandless, SE | 1 |
| Zori, R | 1 |
| Hainline, B | 1 |
| Ah Mew, N | 1 |
| Canavan, C | 1 |
| Vescio, T | 1 |
| Kok, T | 1 |
| Porter, MH | 1 |
| Berry, SA | 2 |
| O'Donnell-Luria, AH | 1 |
| Lin, AP | 1 |
| Merugumala, SK | 1 |
| Rohr, F | 1 |
| Waisbren, SE | 1 |
| Lynch, R | 1 |
| Tchekmedyian, V | 1 |
| Goldberg, AD | 1 |
| Bellinger, A | 1 |
| McFaline-Figueroa, JR | 1 |
| Simon, T | 1 |
| Gershanik, EF | 1 |
| Levy, BD | 1 |
| Cohen, DE | 1 |
| Samuels, MA | 1 |
| Berry, GT | 2 |
| Frank, NY | 1 |
| van Straten, G | 1 |
| de Sain-van der Velden, MGM | 1 |
| van Geijlswijk, IM | 1 |
| Favier, RP | 1 |
| Mesu, SJ | 1 |
| Holwerda-Loof, NE | 1 |
| van der Ham, M | 1 |
| Fieten, H | 1 |
| Rothuizen, J | 1 |
| Spee, B | 1 |
| Verhoeven-Duif, NM | 1 |
| Wilnai, Y | 1 |
| Blumenfeld, YJ | 1 |
| Cusmano, K | 1 |
| Hintz, SR | 1 |
| Alcorn, D | 1 |
| Benitz, WE | 1 |
| Berquist, WE | 1 |
| Bernstein, JA | 1 |
| Castillo, RO | 1 |
| Concepcion, W | 1 |
| Cowan, TM | 1 |
| Cox, KL | 1 |
| Lyell, DJ | 1 |
| Esquivel, CO | 1 |
| Homeyer, M | 1 |
| Hudgins, L | 1 |
| Hurwitz, M | 1 |
| Palma, JP | 1 |
| Schelley, S | 1 |
| Akula, VP | 1 |
| Summar, ML | 1 |
| Enns, GM | 2 |
| Brossier, D | 1 |
| Goyer, I | 1 |
| Ziani, L | 1 |
| Marquis, C | 1 |
| Mitchell, G | 1 |
| Ozanne, B | 1 |
| Chen, C | 1 |
| Bain, KB | 1 |
| Iuppa, JA | 1 |
| Yusen, RD | 1 |
| Byers, DE | 1 |
| Patterson, GA | 1 |
| Trulock, EP | 1 |
| Hachem, RR | 1 |
| Witt, CA | 1 |
| Orton, DJ | 1 |
| Gifford, JL | 1 |
| Seiden-Long, I | 1 |
| Khan, A | 1 |
| de Koning, L | 1 |
| Nagasaka, H | 1 |
| Yorifuji, T | 1 |
| Kobayashi, K | 1 |
| Takikawa, H | 1 |
| Komatsu, H | 1 |
| Inui, A | 1 |
| Fujisawa, T | 1 |
| Miida, T | 1 |
| Tsukahara, H | 1 |
| Takatani, T | 1 |
| Hayashi, H | 1 |
| Laryea, MD | 1 |
| Herebian, D | 1 |
| Meissner, T | 1 |
| Mayatepek, E | 1 |
| Houston, B | 1 |
| Reiss, KA | 1 |
| Merlo, C | 1 |
| Honda, S | 1 |
| Yamamoto, K | 1 |
| Sekizuka, M | 1 |
| Oshima, Y | 1 |
| Nagai, K | 1 |
| Hashimoto, G | 1 |
| Kaneko, H | 1 |
| Tomomasa, T | 1 |
| Konno, Y | 1 |
| Horiuchi, R | 1 |
| MacArthur, RB | 2 |
| Altincatal, A | 1 |
| Tuchman, M | 2 |
| Bunchman, TE | 1 |
| Barletta, GM | 1 |
| Winters, JW | 1 |
| Gardner, JJ | 1 |
| Crumb, TL | 1 |
| McBryde, KD | 1 |
| Jalan, R | 1 |
| Wright, G | 1 |
| Davies, NA | 1 |
| Hodges, SJ | 1 |
| Rhead, WJ | 1 |
| Brusilow, SW | 1 |
| Hamosh, A | 1 |
| Shih, VE | 1 |
| Summar, M | 1 |
| Batshaw, ML | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure/Severe Acute Liver Injury[NCT01548690] | Phase 2 | 47 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| A Phase 2, Open-Label, Switch-Over, Dose-Escalation Study of the Safety and Tolerability of HPN-100 Compared to Buphenyl® (Sodium Phenylbutyrate) in Patients With Urea Cycle Disorders[NCT00551200] | Phase 2 | 14 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To evaluate the effect of OCR-002 on ammonia levels in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: Baseline and 72 Hours
| Intervention | Percent Change (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 41.2 |
| Maximum Dose Level 6.65 g/24h | 16.6 |
| Maximum Dose Level 10 g/24h | 41.8 |
| Maximum Dose Level 20g/24h | 38.4 |
To evaluate the steady state pharmacokinetic and pharmacodynamic profile of OCR-002 in patients with impaired and intact renal function using urinary phenylacetylglutamine (PAGN) as a surrogate marker (NCT01548690)
Timeframe: 24 Hours after last infusion
| Intervention | micrograms per millileter (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 65.6 |
| Maximum Dose Level 6.65 g/24h | 32.2 |
| Maximum Dose Level 10 g/24h | 33.4 |
| Maximum Dose Level 20g/24h | 104.9 |
The orientation log focuses on orientation to place, time, and circumstance. There are 10 items on the orientation log, which are scored 0-3. A spontaneous correct response is awarded 3 points. A spontaneous response that is lacking or incorrect, but a correct response is provided following a logical cue is awarded 2 points. A score of 1 is given if spontaneous and cued responses are lacking or incorrect, but a correct response is provided in a recognition format. A score of 0 is given if the spontaneous, cued, or recognition format does not generate a correct answer. Scores from the 10 items are summed and the final score ranges from 0 to 30. (NCT01548690)
Timeframe: 30 Days
| Intervention | units on a scale (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 23.8 |
| Maximum Dose Level 6.65 g/24h | 24.0 |
| Maximum Dose Level 10 g/24h | 24.0 |
| Maximum Dose Level 20g/24h | 24.0 |
The West Haven Criteria (WHC) for Hepatic Encephalopathy measures the severity of encephalopathy and patient's level of consciousness. The scale ranges from 0 to 4; a minimum score of 0 represents a better outcome, and a maximum total score of 4 represents a worse outcome. A score of 0 corresponds to normal consciousness and behavior and normal neurological examination. A score of 1 corresponds to mild lack of awareness, shortened attention span, and impaired addition or subtraction; mild asterixis or tremor. A score of 2 corresponds to lethargy, disorientated or inappropriate behavior, obvious asterixis; slurred speech. A score of 3 corresponds to somnolent but arousable, gross disorientation or bizarre behavior, muscle rigidity and clonus; hyperreflexia. A score of 4 corresponds to coma and decerebrate posturing. (NCT01548690)
Timeframe: 120 hours from start of infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 2.4 |
| Maximum Dose Level 6.65 g/24h | 3.2 |
| Maximum Dose Level 10 g/24h | 1.6 |
| Maximum Dose Level 20g/24h | 1.8 |
To evaluate the safety and tolerability of OCR-002 in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 0 |
| Maximum Dose Level 6.65 g/24h | 0 |
| Maximum Dose Level 10 g/24h | 0 |
| Maximum Dose Level 20g/24h | 0 |
(NCT00551200)
Timeframe: during the period on 100% Buphenyl (up to 4 weeks) or HPN-100 (up to 10 weeks)
| Intervention | participants (Number) |
|---|---|
| Buphenyl | 7 |
| HPN-100 | 5 |
(NCT00551200)
Timeframe: during the period subjects on 100% Buphenyl (up to 4 weeks) or HPN-100 (up to 10 weeks)
| Intervention | participants (Number) |
|---|---|
| Buphenyl | 1 |
| HPN-100 | 0 |
(NCT00551200)
Timeframe: End of Study
| Intervention | participants (Number) | |
|---|---|---|
| prefer Buphenyl | prefer HPN-100 | |
| Buphenyl to HPN-100 | 1 | 9 |
measured AUC0-24 (Area under the curve from time 0 (pre-dose) to 24 hours) for each metabolite in plasma. Data were collected at 30 minutes and 1, 2, 4, 5, 6, 8, 10, 12, and 24 hours post-first dose. (NCT00551200)
Timeframe: At steady state (1 week) on each medication (Buphenyl® alone, HPN-100 alone)
| Intervention | μg*h/mL (Mean) | ||
|---|---|---|---|
| AUC0-24 PBA (phenylbutyrate) in plasma | AUC0-24 PAA (phenylacetate) in plasma | AUC0-24 PAGN (phenylacetylglutamine) in plasma | |
| HPN-100 Steady State | 540 | 575 | 1098 |
| NaPBA Steady State | 740 | 596 | 1133 |
Data were collected at pre-first dose and at 30 minutes and 1, 2, 4, 5, 6, 8, 10, 12, and 24 hours post first dose. (NCT00551200)
Timeframe: At steady state (1 week) on each medication (Buphenyl® alone, HPN-100 alone), and at steady state (1 week) after each dose escalation
| Intervention | μmol/L (Mean) | |
|---|---|---|
| in peak | in TNAUC (time-normalized area under the curve) | |
| HPN-100 Steady State | 56.3 | 26.5 |
| NaPBA Steady State | 79.1 | 38.4 |
2 reviews available for phenylacetic acid and Hyperammonemia
| Article | Year |
|---|---|
Consensus guidelines for management of hyperammonaemia in paediatric patients receiving continuous kidney replacement therapy.
Topics: Arginine; Carnitine; Child; Child, Preschool; Continuous Renal Replacement Therapy; Delphi Technique | 2020 |
Alternative pathway therapy for urea cycle disorders: twenty years later.
Topics: Amino Acid Metabolism, Inborn Errors; Animals; Arginine; Humans; Hyperammonemia; Phenylacetates; Phe | 2001 |
1 trial available for phenylacetic acid and Hyperammonemia
| Article | Year |
|---|---|
Survival after treatment with phenylacetate and benzoate for urea-cycle disorders.
Topics: Adolescent; Adult; Age Factors; Age of Onset; Amino Acid Metabolism, Inborn Errors; Ammonia; Carbamo | 2007 |
17 other studies available for phenylacetic acid and Hyperammonemia
| Article | Year |
|---|---|
Pharmacokinetics, safety, and tolerability of sodium phenylacetate and sodium benzoate in healthy Japanese volunteers: A phase I, single-center, open-label study.
Topics: Adult; Benzoates; Child; East Asian People; Healthy Volunteers; Humans; Hyperammonemia; Infant; Phen | 2023 |
Pharmacokinetics, safety, and tolerability of sodium phenylacetate and sodium benzoate in healthy Japanese volunteers: A phase I, single-center, open-label study.
Topics: Adult; Benzoates; Child; East Asian People; Healthy Volunteers; Humans; Hyperammonemia; Infant; Phen | 2023 |
Pharmacokinetics, safety, and tolerability of sodium phenylacetate and sodium benzoate in healthy Japanese volunteers: A phase I, single-center, open-label study.
Topics: Adult; Benzoates; Child; East Asian People; Healthy Volunteers; Humans; Hyperammonemia; Infant; Phen | 2023 |
Pharmacokinetics, safety, and tolerability of sodium phenylacetate and sodium benzoate in healthy Japanese volunteers: A phase I, single-center, open-label study.
Topics: Adult; Benzoates; Child; East Asian People; Healthy Volunteers; Humans; Hyperammonemia; Infant; Phen | 2023 |
Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders.
Topics: Age of Onset; Ammonia; Child, Preschool; Female; Glycerol; Humans; Hyperammonemia; Infant; Infant, N | 2021 |
Brain MRS glutamine as a biomarker to guide therapy of hyperammonemic coma.
Topics: Brain; Coma; Female; Gastric Bypass; Glutamates; Glutamine; Humans; Hyperammonemia; Magnetic Resonan | 2017 |
Saline is as effective as nitrogen scavengers for treatment of hyperammonemia.
Topics: Animals; Dogs; Female; Hyperammonemia; Male; Nitrogen; Phenylacetates; Random Allocation; Saline Wat | 2017 |
Prenatal treatment of ornithine transcarbamylase deficiency.
Topics: Ammonia; Drug Combinations; Female; Glutamine; Humans; Hyperammonemia; Infant, Newborn; Male; Mutati | 2018 |
Influence of implementing a protocol for an intravenously administered ammonia scavenger on the management of acute hyperammonemia in a pediatric intensive care unit.
Topics: Acute Disease; Ammonia; Canada; Child; Child, Preschool; Female; Humans; Hyperammonemia; Infant; Inf | 2019 |
Hyperammonemia Syndrome After Lung Transplantation: A Single Center Experience.
Topics: Aged; Ammonia; Arginine; Biomarkers; Carnitine; Combined Modality Therapy; Decontamination; Female; | 2016 |
Critically High Plasma Ammonia in an Adolescent Girl.
Topics: Ammonia; Arginine; Child; Clinical Chemistry Tests; Diagnostic Errors; Fatigue; Female; Fever; Heada | 2016 |
Favorable effect of 4-phenylacetate on liver functions attributable to enhanced bile salt export pump expression in ornithine transcarbamylase-deficient children.
Topics: Adenosine Triphosphatases; Adolescent; Arginine; ATP Binding Cassette Transporter, Subfamily B, Memb | 2010 |
Simultaneous LC-MS/MS determination of phenylbutyrate, phenylacetate benzoate and their corresponding metabolites phenylacetylglutamine and hippurate in blood and urine.
Topics: Benzoates; Biomarkers; Biotransformation; Calibration; Chromatography, Reverse-Phase; Glutamine; Hip | 2010 |
Healthy, but comatose.
Topics: Adult; Brain Edema; Carbohydrates; Enteral Nutrition; Glucose; Humans; Hyperammonemia; Insulin; Male | 2011 |
Successful treatment of severe hyperammonemia using sodium phenylacetate powder prepared in hospital pharmacy.
Topics: Adolescent; Chemistry, Pharmaceutical; Humans; Hyperammonemia; Male; Pharmacy Service, Hospital; Phe | 2002 |
Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; | 2004 |
Phenylacetate and benzoate clearance in a hyperammonemic infant on sequential hemodialysis and hemofiltration.
Topics: Ammonia; Hemofiltration; Humans; Hyperammonemia; Infant, Newborn; Phenylacetates; Renal Dialysis; So | 2007 |
L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy.
Topics: Ammonia; Drug Therapy, Combination; Hepatic Encephalopathy; Humans; Hyperammonemia; Liver; Models, B | 2007 |
Alternative-pathway therapy for hyperammonemia.
Topics: Amino Acid Metabolism, Inborn Errors; Humans; Hyperammonemia; Phenylacetates; Sodium Benzoate; Urea | 2007 |
Current strategies for the management of neonatal urea cycle disorders.
Topics: Algorithms; Amino Acid Metabolism, Inborn Errors; Antimetabolites, Antineoplastic; Arginine; Dialysi | 2001 |